Relay Medical, Glow Lifetech Announce Successful Phase II COVID-19 Trials Based On Their Tech

Relay Medical (CSE: RELA) last night announced a positive development related to Glow LifeTech, a private firm in which the company has significant ownership of. Glow has seen a successful phase II clinical trial completed on a COVID-19 treatment candidate, which is based on its MyCell Technology.

Glow’s partner Swiss Pharmacan AG and MGC Pharma announced the full results of the study, which was a phase II double-blind placebo-controlled clinical trial on the anti-inflammatory treatment known as ArtemiC. The treatment is based on Glow’s MyCell technology, which is a delivery system technology that Glow has the exclusive rights license for manufacturing, sales and marketing on certain cannabis and nutraceutical ingredients within North America.

The study successfully met all primary and secondary endpoints within the study, while also demonstrating that it is able to improve the clinical outcome of COVID-19 patients. The study involving 50 patients show that ArtemiC statistically significantly improved the clinical outcome of COVID-19 patients when compared to the placebo group. No patients that received the treatment required additional oxygen, mechanical ventilation, or intensive care, which compares to 23.4% of the placebo group whom did require such additional measures.

“These are very exciting results for Glow’s MyCell Technology™ and the ArtemiC™ formulation. We are pleased that our innovative MyCell Technology™ is helping to power a natural formulation that shows promising ability to improve and expedite the recovery of COVID-19 patients. It demonstrates the long term potential of MyCell Technology™ to power next generation natural health products with science-backed efficacy and safety.”

Clark Kent, CEO of Glow LifeTech

A Phase III clinical trial is now slated to begin in the first half of 2021. The trial is currently identified as being an international multicentre study, which focuses on encompassing a wide range of inflammatory indications for the use of the treatment.

Relay Medical last traded at $0.29 on the CSE.


FULL DISCLOSURE: Relay Medical Corp is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Relay Medical Corp on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Is Gold’s Bull Market About to Hit Junior Stocks? | Ken Armstrong – Westhaven Gold

Surge Battery Metals: The Nevada North Lithium PEA

Silver @ $36 & We’re Still 200M Oz Short | Paul Andre Huet – Americas Gold and Silver

Recommended

Goliath Resources Closes Out Funding Round With Total Gross Proceeds Of $27.1 Million

Silver47 Kickstarts 4,000 Metre Drill Campaign At Red Mountain Project

Related News

Relay Medical Sees Joint Venture Awarded USAID Contract In Africa

Relay Medical Corp (CSE: RELA) continues to see success with its joint venture with that...

Tuesday, December 8, 2020, 07:09:11 AM

Health Canada’s Move To Approve Home Based COVID-19 Testing Bodes Well For Relay Medical

Last week, Health Canada formally changed its stance on at-home COVID-19 test kits as it...

Monday, September 7, 2020, 11:24:00 AM

Relay Medical Sees First Deployment of Fionet Software To Track COVID-19

Relay Medical (CSE: RELA) last night identified a significant development for its joint venture with...

Friday, September 11, 2020, 08:42:30 AM

Relay Medical Forms Clinical, Strategic Advisory Boards

Relay Medical (CSE: RELA) early this morning announced that it has formed strategic boards to...

Tuesday, September 22, 2020, 08:41:45 AM

Relay Medical Receives $3.0 Million From Option And Warrant Exercises

Relay Medical (CSE: RELA) last night announced that the company has seen total cash inflows...

Friday, February 12, 2021, 07:58:08 AM